4-(1H-imidazol-4-ylmethyl)piperidine

05/01/2011 - "The results indicated the efficacy of immepip systemic administration in an experimental model of diabetic hyperalgesia. "
05/01/2011 - "5 and 30 mg/kg doses of immepip reversed chemical hyperalgesia in diabetic rats. "
08/15/2019 - "Prior administration of thioperamide (4 μg/site) increased the suppressive effects induced by histamine and inhibited immepip (2 μg/site)-induced hyperalgesia and aversion. "
05/01/2011 - "In this study, the efficacy of systemic administration of selective H3 receptor agonist, immepip (1, 5 and 30 mg/kg), and antagonist, thioperamide (5, 15 and 30 mg/kg), was investigated on hyperalgesia during the formalin test in streptozocin (STZ)-induced diabetic rats. "

05/01/2011 - "The 1 mg dose of immepip did not alter pain behaviors in control and diabetic groups compared to the respective control ones. "
03/01/2005 - "In addition, immepip (5 mg/kg, subcutaneous) significantly attenuated formalin-induced flinching, but not formalin-induced licking, during both phase 1 and phase 2, suggesting that H 3 agonists might be effective in treating some forms of clinically relevant pain. "

09/01/2010 - "The involvement of histamine H(3) receptors in modulation of nociception in a model of elevated endogenous opioid tone, cholestasis, was investigated in this study using immepip and thioperamide as selective H(3) receptor agonist and antagonist respectively. "

05/01/2011 - "Immepip at any doses used in this study did not affect the body weight and plasma glucose levels of treated animals. "

06/01/2006 - "Coadministration of immepip (1 mg/kg) with L-dopa (15 mg/kg) was associated with significantly less total dyskinesia than L-dopa alone. "
06/01/2019 - "Chronic administration of the histamine H3 receptor agonist immepip decreases L-Dopa-induced dyskinesias in 6-hydroxydopamine-lesioned rats."
10/15/2014 - "The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats."
06/01/2006 - "When dyskinesia was separately rated as chorea and dystonia, coadministration of L-dopa with either immepip or imetit (both 10 mg/kg) significantly reduced chorea but had no effect on dystonia. "
10/15/2014 - "In the MPTP-treated common marmoset exhibiting dyskinesia to l-dopa, immepip alone induced retching and in combination with l-dopa administered subcutaneously or orally induced the rapid onset of retching and vomiting which was not controlled by pretreatment with domperidone. "